GLP-1 medications are administered as once-weekly subcutaneous injections, typically into the abdomen, thigh, or upper arm
As GLP-1 use grows, HairSmart expects this to become one of the defining hair loss conversations of the next few years, not because the medications are doing something entirely new to the body, but because they're accelerating causes of hair loss that have existed all along, just rarely discussed in the open
As with all B-class GPCRs, GLP1R features an N-terminal extracellular domain (ECD) consisting of 100-150 residues, connected to a complete 7-transmembrane (7TM) domain, which is a hallmark of all GPCRs
These findings have substantially improved scientific understanding of IGF-1-mediated intracellular signaling, although the majority of evidence is derived from in vitro and animal research
10.1242/jcs.02793 3 ArckP